Answers are grounded in this paper and cite their sources.
Background: Interpretation of postmortem methadone concentration is a major challenge in forensic toxicology because therapeutic and fatal concentrations overlap. As methadone is administered as a racemic mixture, and its enantiomers are stereoselectively metabolized by polymorphic cytochrome P450 (CYP) enzymes, inherited differences in CYP activity may influence postmortem enantiomeric distribution. In this study, whether genetically predicted CYP phenotypes are associated with postmortem methadone enantiomeric distribution was investigated. Methods: Eight methadone-related deaths were prospectively included. Total methadone and R- and S-methadone concentrations were determined in paired femoral blood and vitreous humor samples, using a validated enantioselective liquid chromatography–tandem mass spectrometry method. Multiple CYP enzymes were genotyped using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and metabolizer phenotypes were assigned according to current Clinical Pharmacogenetics Implementation Consortium/Dutch Pharmacogenetics Working Group recommendations. Enantiomeric distribution was assessed using S-methadone/total methadone, R-methadone/total methadone, and S/R-methadone ratios. Results: Enantiomeric ratios were close to racemic equilibrium in femoral blood and vitreous humor, despite considerable interindividual variability in absolute methadone concentrations. There was no consistent association between predicted CYP phenotypes or enantiomeric ratios across biological matrices. Overall, enantiomeric distributions were highly concordant between femoral blood and vitreous humor. Conclusions: Within the limitations of this exploratory series, there was no consistent association between predicted CYP phenotypes and postmortem methadone enantiomeric distribution. The variability may reflect the contribution of acquired and other nongenetic factors, including phenoconversion. Larger integrative studies that combine pharmacogenetics, toxicological data, and clinical data are warranted.
No takes yet. Share an insight, caveat, or question.
Tbibi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: